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myoelectric cycle, which further consists of following 4 phases that are summarized in Figure 1 and Table 1.
FACTORS INFLUENCING GASTRIC 
RETENTION OF DOSAGE FORMSThe anatomy and physiology of the stomach contain parameters to be considered in the development of gastroretentive dosage forms.Important parameters controlling the gastric retention are as follows:
Density of Dosage FormsThe density of a dosage form affects the gastric emptying rate and determines the location of the system in the stomach. Dosage forms which are having density lower than the gastric contents can float to the surface, while high-density systems sink to  bottom of the stomach.[7] Both the positions may isolate the dosage system from the pylorus part of the stomach. A density of <1.0 g/cm3 is required to show floating property.[8] Streubel et al. prepared the single-unit floating tablets based on polypropylene[9] foam powder and matrix-forming polymer and the incorporation of highly porous foam powder in matrix tablets provided density much lower than the density of the release medium. A 17% wt/wt foam powder (based on the mass of tablet) showed in vitro release for at least 8 h. It was thus concluded that varying the ratios of matrix-forming polymers and the foam powder could alter the drug release patterns effectively. The Chitosan-Carbopol 940 mixed matrices that were used to modify release rates in hydrophilic matrix tablets prepared by direct compression, and incorporation of the highly porous low-density copolymer and poly(styrene-divinylbenzene) Copolymer in the matrix tablets provides densities that were lower than the density of the release medium and 17% w/w low-density copolymer (based on the mass of the tablet) was sufficient to achieve proper in vitro floating behavior for at least 8 h.[10]
INTRODUCTIONGastroretentive system ensures that the dosage form remains within the gastric region for the longer duration of time. This provides the advantage that the gastric retention time (GRT) for such drug is improved in comparison to conventional dosage form and also the minimum effective concentration of drug remains maintained in systemic circulation for longer duration.[1]Gastroretentive drug delivery systems prolong the dosing intervals and hence patient compliance is improved.[2] Gastroretentive drug delivery systems provide the support for reducing the frequent dosing of the drug by producing a controlled delivery within the stomach for longer duration. Although formulations or novel dosage forms such as nanoparticle, microspheres, and liposome can also be used for controlled release (CR) effect, but gastroretentive system is considered a much better alternative for improved absorption through the stomach.[3]
GASTRIC EMPTYING TIME (GET) AND 
MOTILITYGET occurs during both fasting as well as fed states. GET is the time required to pass drug from the stomach to the small intestine. It is the rate limiting step for drug absorption because the intestine is the major site for absorption. In general, bioavailability of the drugs is increased by rapid gastric emptying. For drugs that degrade in gastric environment, faster onset is required.[4] The drugs which are poorly soluble at alkaline pH and are majorly absorbed from the stomach or proximal part of the intestine their dissolution is promoted by delayed gastric emptying. However, the pattern of motility is distinct in the two states. The interdigestive series of electrical events takes place during the fasting states, which cycle both through the stomach and intestine every 2–3 h.[5] This is defined as the interdigestive myoelectric cycle or migrating 
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Shape and Size of the Dosage FormShape and size of the dosage forms are important in designing the indigestible single-unit solid dosage forms.[11] Due to the larger size of the dosage form, it will not quickly pass through the pyloric antrum into the intestine.[12] Garg and Sharma[13] reported that tetrahedron- and ring-shaped devices had the better gastric residence time as compared to other shapes. The diameter of the dosage unit is also an important formulation parameter. Dosage forms that are having a diameter of more than 7.5 mm show a better gastric residence time as compared with one having 9.9 mm.
Single- or Multiple-unit FormulationMultiple unit formulations show a more predictable release profile. The insignificant impairing of performance due to the failure of units allows coadministration of units with different release profiles or containing incompatible substances, and thus, they permit a larger margin of safety against dosage form failure compared with single-unit dosage forms.[11] Sungthongjeen 
et al.[14] developed a multiple-unit floating system which was prepared by extrusions spheronization and consisted of drug-loaded core pellets, and then, it was coated with double layers of an inner gas forming layer (sodium bicarbonate) and a outer with gas-entrapped membrane of an aqueous colloidal polymer dispersion. Thus, this system achieved immediate floating and buoyancy over a period of 24 h with sustained drug release. Sungthongjeen et al.[15] prepared the floating multilayer coated tablets in which theophylline was inside the core of the tablet, and it was further coated with a protective layer of hydroxypropyl methylcellulose (HPMC) and a gas forming layer of sodium 
bicarbonate and a polymeric membrane of high flexibility (Eudragit RL30D), respectively. The polymeric film had high flexibility (Eudragit RL30D) and was capable to entrap generated CO2 and had subsequent good floating properties. Ichigawa et 
al.[16] developed a floating system by coating the sustained release granules with tartaric acid layer, sodium bicarbonate layer, and polymeric film which consisted of polyvinyl acetate and shellac.
Food Intake and Its NatureFood intake, viscosity and volume of food, caloric value, and frequency of feeding are the factors that have a profound effect on the gastric retention of dosage forms. The presence or absence of food influences the GRT of the dosage form. Usually, the presence of food in the gastrointestinal tract (GIT) improves the gastric retention for a longer period, by allowing its stay at the absorption site. Again, increase in acidity and caloric value slows down GET, which thus improves the gastric retention of dosage forms (Garg et al, 2008).[5] Sugihara et al.[17] studied the effect of food intake on gastroretentive and mucoadhesive submicron-sized chitosan-coated liposomes. In this study, chitosan-coated liposomes and uncoated liposomes containing fluorescent dye were orally administered to fasted or fed rats. The stomach and small intestine of rats were removed after a certain duration of time. The dye retentive properties were quantitatively confirmed by measuring the amount of dye in each part.
Effect of Gender, Posture, and AgeIn general, females have slower gastric emptying rates than male partner. The postural effect does not have any significant difference in the mean GRT for individuals in the upright, ambulatory, and supine state. However, in elderly persons, gastric emptying is slowed down.[18] Timmermans et al.[19] studied the effect of buoyancy, posture, and nature of meals on the gastric emptying process using in vivo gamma scintigraphy. In this study, floating and non-floating capsules of 3 different sizes having a diameter of 4.8 mm (small units), 7.5 mm (medium units), and 9.9 mm (large units) were considered. Then, the floating and non-floating were compared, and it was concluded that, regardless of their sizes, the floating dosage units remained buoyant on the gastric contents throughout their residence in the GIT. It was also observed that the floating units had the longer gastric residence time for small and medium units, while no significant difference was seen between the two types of large unit dosage forms, and it was further  concluded that in supine position large dosage forms (both conventional and floating) experience prolonged retention.
Formulation techniquesDue to physiological variation in the gastric environment, the aim to achieve retention of drug in the stomach could be fulfilled by modifying drug delivery systems. Thus, various approaches have been used to retain drug in the gastric environment for the longer duration of time. The detail is shown in Figure 2. The different patented technologies are summarized in Table 2.
HIGH-DENSITY (SINKING) SYSTEM OR 
NON-FLOATING DRUG DELIVERY SYSTEM 
(FDDS)This approach involves the formulation of dosage forms with the density more than the density of normal stomach content 
Figure 1: The schematic representation of the gastrointestinal motility 
pattern
Table 1: Different phases involved in 
interdigestive myoelectric cycle
Phase‑1(basal phase) It lasts for 40–60 min with contractions which 
are rare
Phase‑2(preburst phase) It lasts for 40–60 min with intermittent action 
potential and contractions. The intensity and 
frequency increase gradually as the phase 
progresses
Phase‑3(burst phase) It lasts for 4–6 min and it includes intense and 
regular contractions which remain for short 
period this is the reason that all the undigested 
material is swept out of stomach down to small 
intestine. It is also called as housekeeper wave
Phase‑4 The period of transition from phase‑3 to 
phase‑1 remains for 0–5 min
Source: Talukder et al. (2004)[6]
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(~1.004 g/cm3). They are formulated by coating drug on a heavy core or mixed with inert materials such as iron powder, barium sulfate, zinc oxide, and titanium oxide.[20] The materials increase the density up to 1.5–2.4 g/cm3. A density that seems to be necessary for significant prolongation of gastric residence time must be close to 2.5 g/cm Rouge et al.[21] performed a comparative study with an immediate release system, a high-density system, and a low-density system. The results depicted gastric residence 
times of 0.5, 1, and 2 h, respectively, indicating that the high-density system did not demonstrate any significant extension of the gastric residence time. However, the effectiveness of this system in human beings was not observed[22] and no such system existed in market. Devereux et al. [23] prepared pellets  with density of at least 1.5 g/mland showed that they have significantly higher residence time both in fasted and fed state. Tuleu et al.[24] also prepared three types of non-disintegrating pellets with the same 
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Figure 2: Different approaches to achieve gastric retention
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Drug Dosage form Purpose of 
patent
Polymer used Evaluation Reference
Metformin 
hydrochloride
The formulation 
consists of gastric 
retention pellet 
of metformin 
hydrochloride
Gastroretention 
patent for 
mucoadhesive 
delivery system
HPMC, Na alginate, 
Na‑CMC, carbomer 
934, Chitosan
Adhesion studies were done using texture 
analyzer. In vitro dissolution tests were 
performed according to the dissolution test 
method of USP XXII. In vivo study was performed, 
and the concentration of metformin in the 
solution was measured by HPLC
[39]
Rosiglitazone A CR oral dosage 
form of rosiglitazone 
in the form of pellets
Gastroretentive 
technology 
for swelling 
and expanding 
systems
Polymeric matrix is 
HMC, a CMC, oral 
combination of 
alkyl celluloses, is 
poly (ethylene oxide)
This solid polymeric matrix on imbibitions 
of water swells, and retains within HEC, 
HPC, HPMC, hour, ≥40 weight percent of the 
rosiglitazone after immersion in simulated gastric 
fluid
[40]
Heparin and insulin A bilayered SR tablet 
or caplet composition 
of heparin and insulin
Gastroretentive 
technology 
for swelling 
and expanding 
systems
The release‑controlling 
polymer was 
polyethylene oxide, 
polyethylene, and 
Carbopol® 934 P
The in vitro dissolution of both SNAC and heparin 
in simulated intestinal fluid was measured. It was 
believed that this formulation could be retained 
in the stomach for much longer that the 4 h
[41]
Flouroquinolones, 
amoxicillin, cephalexin, 
metformin, gliclazide, 
diltiazem, metoprolol
Bouyant biconvex 
caplets were formed
Patent for 
floating 
mechanism
Methyl cellulose, 
HPMC, and HPC with 
the exclusion of low 
substituted HPC were 
used as gelling agents
Dissolution study was done in 0.1 N HCl using 
USP type‑II apparatus at 100 rpm
[42]
Methotrexate alone or 
in combination with 
folates
Monolithic SR tablet 
of methotrexate 
alone or in 
combination with 
folates
Patent covering 
swelling, 
floating and 
mucoadhesive 
mechanisms
Polymers used are 
cellulose derivative 
such as a hydrophilic 
polymer which 
comprises Carbopol, 
HPC, and HMC etc.
In vitro dissolution was done in USP 23 paddle 
app 2 at a paddle speed of 50 rpm in 900 ml 
SGF (pH 1.2, no enzyme) at 37±0.20C for 24 
h. Floating time and floating lag time and 
bioadhesive strength was measured.
[43]
Acyclovir A CR oral tablet Gastroretentive 
technology 
for swelling 
and expanding 
systems
Stearyl macrogol 
glyceride polyethylene 
oxide, Crospovidone 
etc.
Swelling studies were determined in 0.1 N HCL 
and combination of a swelling enhancerand 
polymer resulted in faster rate of swelling, as was 
desired for gastroretention
[44]
Bupropion HBr Matrix type CR tablet 
dosage form
Gastroretentive 
Technology 
for swelling 
and expanding 
systems
Combination of 
polymers such as EC 
and the was HEC and 
HPMC
In vitro dissolution of formulations in different 
USP‑3 Media, i.e., SGF, pH 1.2, acetate Buffer 
ph 4.5, and phosphate buffer ph 6.8 over 16 h is 
done.
[45]
Gabapentin and 
metformin
Gabapentin SR and 
metformin SR tablets
Gastroretentive 
technology 
for swelling 
and expanding 
systems
Combination of HPC 
and HPMC was used in 
sustain release study.
The bioavailability of gabapentin SR tablets, 
made by wet granulation process, was evaluated 
in healthy human volunteers.
[46]
Nadolol and 
metoprolol
Oral CR matrix 
tablet formulation 
of nadolol, and 
metoprolol
Gastroretentive 
technology 
for swelling 
and expanding 
systems
The first component 
was PVA combined 
with PVP, and 
second component 
was cellulose ether 
polymer
The acute reduction in airway function (FEV‑i) 
was measured in subjects with mild asthma 
with the first 10 mg dose of once‑daily 
corgard (nadolol). The peak serum levels of 
nadolol occurred in 3.5 h after administration
[47]
Parathyroid hormone Gastro retentive 
drug delivery 
system enclosed in a 
capsule consisting of 
parathyroid hormone
Gastroretentive 
technology 
for swelling 
and expanding 
systems
Polymers selected 
were cross‑linked 
hydrolyzed gelatin 
and polymeric strips 
comprised of eudragit 
L100, ethylcellulose, 
and triacetin
The results of the stability study in various buffer 
solutions showed that the peptide showed 
decreased stability at PH>7 and at pH=1.2
[48]
Thrombin inhibitor A monolayered 
SR dosage form of 
Thrombin inhibitor
Patent for 
floating 
mechanism
HPMC, HPC, PVA A pharmacokinetic study in dogs by giving iv 
bolus dose was done. The slug capsules increased 
the APTT to the therapeutic range of 1.5–2.5 at 
the 24 h time point.
[49]
(Contd...)
Table 2: Various gastroretentive patented technologies
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size and different densities and found that with an increase in density GI transit time increases.
FDDSFDDS or hydrodynamically controlled systems are low-density systems that float over the gastric contents because of their sufficient buoyancy and remain buoyant in the stomach for prolonged period of time without affecting the gastric emptying rate.[25] The drug is released slowly from the floating system at a desired rate. The residual system is removed from the stomach after the release of drug. According to buoyancy retention principle, a minimal gastric content is needed to allow the proper achievement of the buoyancy; however, a minimal level of floating force (F) is also  required to keep the dosage form reliably buoyant on the surface of the meal.[26] The mechanisms of the floating system are shown in Figure 3.[27]The major requirements for FDDS are that the contents should be released slowly to serve as a reservoir, specific gravity must be maintained lower than gastric contents (1.004–1.01 g/cm3) and be cohesive gel barrier. The inherent low density can be provided by the entrapment of air as in case of hollow chambers or it can be achieved by the incorporation of low-density materials (e.g., fatty material, oils, or foam powder).[28,29]These approaches have been used for the design of floating dosage forms (FDFs) of single- and multiple-unit systems. Streubel et al.[9] proposed a single-unit floating system consisting of polypropylene foam powder, matrix-forming polymers, drug, and filler. The good floating behavior of these systems could be successfully combined with drug release patterns. Single-unit dosage forms are concerned with problems such as sticking together or being obstructed in the GIT which may produce irritation. Multiple unit floating systems reduce the inter and intra subject availabilities in drug absorption as well as lower the possibility of dose dumping. Based on the mechanism of buoyancy, two different technologies that have been utilized are non-effervescent and effervescent in the development of FDDS and various polymers are described in Table 3.
Non-effervescent SystemsNon-effervescent FDDSs are prepared from gel-forming or highly swellable cellulose type hydrocolloids, polysaccharides, 
or matrix-forming polymers such as polyacrylate, polycarbonate, polystyrene, and polymethacrylate.[30] In the first approach, the drug is intimately mixed with a gel-forming hydrocolloid so that when comes in contact with gastric fluid after oral administration and maintain a relative integrity of shape and a bulk density less than unity within the gastric environment.[31] The air trapped by the swollen polymer provides buoyancy to these dosage forms. The excipient used most commonly includes HPMC, polyacrylates, polyvinyl acetate, carbopol, agar, sodium alginate (Alg), calcium chloride, polyethylene oxide, and polycarbonates.[5] This system can be further divided into the subtypes.
Hydrodynamically balanced systemsHydro-dynamically balanced systems contain drug with gel forming hydro-colloids that remain buoyant on the stomach content.[32] They are single-unit dosage form, containing one or more gel-forming hydrophilic polymers such as HPMC, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, polycarbophil,  polyacrylate, polystyrene, agar, carrageenans, or alginic acid.[33,34] The polymers are mixed with drugs and usually administered in hydrodynamically balanced system capsule. The capsule shell dissolves in contact with water and mixture swells to form a gelatinous barrier, which imparts buoyancy to a dosage form for a long period in gastric juice as shown in Figure 4 (Dhiman 
et al., 2011).[35] The continuous erosion of the surface allows water penetration to the inner layers maintaining surface hydration and provides buoyancy to dosage form fatty excipient can be incorporated to give low-density formulations reducing 
Drug Dosage form Purpose of 
patent
Polymer used Evaluation Reference
Amoxicillin and 
clavulanic acid
SR gastroretentive 
amoxicillin and 
clavulanic acid
Patent for 
floating 
mechanism
HPMC. Suitable 
coatings of applied of 
HPMC, HPC, HEC, MC 
or PVP, combinations 
of different polymers 
were used
A pharmacokinetic evaluation of the therapeutic 
system was done in twelve healthy male 
volunteers in fed conditions
[50]
Botulinum toxin type A Botulinum toxin type 
A oral formulation 
consisting 
of polymeric 
microspheres
Gastroretentive 
patent for 
mucoadhesive 
delivery system
A carrier polymer 
of polylactides, 
polyglycolides, and 
polyanhydrides
‑ [51]
APTT: Activated partial thromboplastin time, HPMC: Hydroxypropyl methylcellulose, PVA: Polyvinyl alcohol, HEC: hydroxethyl cellulose, HPC: Hydroxypropyl cellulose, 
CR: Controlled release, PVP: Polyvinyl pyrrolidone
Table 2: (Continued)
Figure 3: Mechanisms of floating system (Patel et al., 2012)
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the erosion. Madopar LP®, based on this system, was marketed during the 1980’s (Bardonnet et al., 2006).[36] Ali et al.[37] developed a hydrodynamically balanced system of metformin as a single-unit floating capsule using various grades of low-density polymers which were prepared by physical blending of metformin and the polymers in varying ratios.The formulation was optimized on the basis of in vitro buoyancy and in vitro release in simulated fed state gastric fluid (citrate phosphate buffer pH 3.0), and the effect of various release modifiers was studied to ensure the delivery of drug from the HBS capsules over a prolonged period. Capsules that were prepared with HPMC K4M and ethyl cellulose (EC) gave the best 
in vitro percentage release and were taken as the optimized formulation. Singh et al.[38] (2010) prepared hydrodynamically balanced system of directly compressible floating-bioadhesive tablets of tramadol using varying amounts of Carbopol 971P (CP) and HPMC. This system was characterized by in vitro drug release profile, buoyancy characteristics and ex vivo bioadhesive strength using texture analyzer and optimized  using a 32 central composite design.
Microballoons/hollow microspheresMicroballoons/hollow microspheres which are loaded with drugs in their other polymer shelf were prepared by simple solvent evaporation or solvent diffusion/evaporation methods to prolong the GRT of the dosage form [Figure 5].[7,59] Commonly used polymers for these systems are polycarbonate, cellulose acetate, calcium Alg, Eudragit S, agar, and low methoxylated pectin. The buoyancy and drug release from dosage form are dependent on the quantity of polymers, the plasticizer polymer ratio, and the solvent used for the formulation. Such type of 
microballoons floated continuously over the surface of an acidic dissolution media containing a surfactant for >12 h.[5] Hollow microspheres are considered to be one of the promising buoyant systems because they combine the advantages of multiple-unit system and good floating. Junyaprasert[60] and Pornsuwannapha prepared hollow microspheres of acyclovir by solvent evaporation diffusion method using Eudragit S 100 as a controlled polymer and found that the highest % yield of the hollow microspheres was obtained with the use of 5:8:2 of dichloromethane:ethanol:isopropanol as a solvent system and stirring at 300 rpm for 60 min. With the increase of drug-to-polymer ratio, the size and percent 
Table 3: Various polymers and their formulation for floating drug delivery systems
Polymer Drug Formulati 
on
In vitro performance Retention time Reference
Sodium alginate Cloxacillin Multiple unit 
alginate‑based 
floating system
The alginate beads showed drug entrapment 
efficiency of 64.63±0.78%, density of 0.90±0.05 
g/cm3, and drug release of 56.72±0.85% in 
simulated gastric fluid (pH 1.2)
The beads showed prolonged 
sustained release ofcloxacillin 
over 8 h in simulated gastric 
fluid (pH 1.2)
[52]
HPMC, Eudragitated 
30D, PEG‑6000
Zolpidem 
tartarate
Multipartic ulate 
floating drug 
delivery system
The dosage form of zolpidem tartrate showed 
release according to biphasic profile of 
dissolution, where the first phase is immediate 
release phase for inducing the sleep and the 
second phase is modified release phase for 
maintaining the sleep upto 10 h
The system floated for about 
10 h
[53]
Guar gum, locust bean 
gum, HPMC K 100M
Ofloxacin Floating matrix 
tablets of 
ofloxacin
Formulation prepared with guar gum started 
floating after 7.83 min and remains buoyant for 8 
h till they were completely eroded
The formulations showed drug 
release from 8 to 12 h
[111]
HPMC, EC, Chitosan Rabeprazole 
sodium
Floating 
microspher es
The microspheres showed drug release for about 
12 h
The microspheres were 
retained for about 12 h
[54]
EC and PEG Ranitidine 
hydrocloride
Floating 
microspheres
The microspheres showed drug loading, 
entrapment, and encapsulation as 23–32, 86–96 
and 75–86% (w/w), respectively
The drug loaded microspheres 
floated for 10 h and sustained 
the drug release over 4–6 h
[55]
Sodium alginate, locust 
bean gum and xanthan 
gum
Acyclovir Floating tablet Floating lag time was from 15 to 120 s and tablet 
of each batch remained buoyant up to 16 h best 
formulation remain buoyant up to 24 h
Formulation containing 60% 
of Locust bean gum and 40% 
sodium alginate showed drug 
release for 24 h
[56]
Metolose 90 SH100, 
000 SR
Zn‑acetate Floating matrix 
tablets
Lag time varied from 1 to 4 min with varying 
amount of effervescent agent and floated for 
about 4 h
The formulation showed 
in vitro drug release for about 
4 h
[57]
HPMC: Hydroxypropyl methylcellulose, EC: Ethyl cellulose
Figure 4: Mechanism of hydrodynamically balanced system
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Mangla, et al.: Gastroretentive systems www.apjhs.comdrug content were increased. Ma et al.[61] prepared multi-unit floating Alg microspheres employing inotropic gelation method. In this technique calcium carbonate was used as gas forming agent and drug release was delayed by adding Chitosan (Cs) into the gelation medium and by coating with Eudragit, respectively. Hence, it was found that the drug encapsulation efficiency of Cs–Alg microspheres was much higher than that the Ca–Alg microspheres and coating the microspheres with Eudragit RS extended the drug release significantly.
Alg beadsTalukdar and Fassihi[62] developed a multiple-unit floating system. They were made using a combination of Ca2+ and low methoxylated pectin (anionic polysaccharide) or Ca2+ low methoxylated pectin and sodium Alg. Multiunit FDFs were developed from freeze-dried calcium Alg. Spherical beads can be prepared by dropping a sodium Alg solution into an aqueous solution of calcium chloride of approximately 2.5 mm in diameter, causing precipitation of calcium Alg.[63] In another study, floating systems comprising of a calcium Alg core separated by an air compartment from membrane of calcium Alg or calcium Alg/polyvinyl alcohol (PVA) were developed. The porous structure that was generated by leaching of PVA, (a water-soluble additive in coating composition) was found to increase the membrane permeability preventing the collapse of air compartment.[64] Shishu et al.[65] prepared a multiple-unit type oral FDF of 5-fluorouracil (5-FU) to prolong gastric residence time, target stomach cancer, and increase drug bioavailability. The floating bead was prepared by dispersing 5-FU together with CaCO3 into a mixture of sodium Alg and HPMC solution and then dripping the dispersion into an acidified solution of calcium chloride, and hence, calcium Alg beads were formed by inotropic gelation and carbon dioxide was developed from the reaction of carbonate salts with an acid. Jaiswal et al. (2009)[66] prepared the multi-unit gastroretentive sustained release dosage form of a water-soluble drug, ranitidine hydrochloride by emulsion gelation technique, and prepared beads using sodium Alg as the polymer and oil were entrapped in the beads by gently mixing or homogenizing oil and water phase containing sodium Alg which was then extruded in to calcium chloride solution. Hence, the beads successfully delivered the drug in the stomach for a prolonged duration of time.
Microporous compartment systemThis approach utilizes the principle of the encapsulation of a drug reservoir inside a microporous compartment with pores along its top and bottom walls.[7] The peripheral walls of the device were completely sealed to prevent any direct contact of the undissolved drug with the gastric surface. The buoyancy chamber in the stomach containing entrapped air causes the delivery system to float in the gastric fluid.[67] The gastric fluid that enters through the aperture dissolves the drug and causes continuous transport of the dissolved drug across the intestine for drug absorption [Figure 6].[68]
Effervescent FDFs
Gas generating systemsThese are matrix type of systems that are prepared with the help of swellable polymers such as methylcellulose and chitosan and various effervescent compounds, for example, sodium bicarbonate, tartaric acid, and citric acid. They are formulated 
in such a way that when they come in contact with the acidic gastric contents, CO2 is liberated and gets entrapped in swollen hydrocolloids, which provide buoyancy to the dosage forms as shown in Figure 7.[1] In vitro studies, the lag time before the unit floats is <1 min, and the buoyancy is prolonged for 8–10 h.[69] 
In vivo experiments in fasted dogs, they showed that mean gastric residence time was increased up to 4 h, compressing the gas generating components in a hydrocolloid-containing layer and the drug in another layer which was formulated for a sustained release effect, thereby producing a bilayered tablet. The different floating systems available in the market are given in Table 4.
Swelling systemThis type of dosage form swell to an extent that prevents their exit from the pylorus. Therefore, the dosage form is retained in the stomach for a longer period of time. Such systems may be named as “plug type systems.” Sustained and controlled drug release may be achieved by selection of polymer of proper molecular weight and swelling of the polymer retards the drug release when it comes in contact with gastric fluid, the polymer imbibes the water and swells.[76] The diagrammatic representation of drug release from swellable system is shown in Figure 8.[7] Arza et al.[77] (2009) developed swellable, floating, and sustained release tablets made using a combination of hydrophilic polymer HPMC, swelling 
Figure 5: Formulation of floating hollow microsphere or microballoon
Figure 6: Microporous compartment system (Shah et al., 2009)
Figure 7: Different types of effervescent generating systems (Majethiya 
et al., 2013)
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agents (crospovidone, sodium starch glycolate, and croscarmellose sodium), and effervescent substance (sodium bicarbonate). It was found that combination of HPMC K100M, crospovidone, and sodium carbonate showed good swelling, drug release, and floating characters which is even better than the CIFRAN OD®.
Raft-forming systemsRaft-forming systems have received attention for the delivery of antacids and drug delivery for GI infections and disorders.[78] This system floats on gastric contents of the stomach. The mechanism involved behind the raft formation includes the formation of viscous cohesive gel in contact with gastric fluids, wherein each portion of the liquid swells forming a continuous layer called a raft. This raft floats on gastric fluids because of its low bulk density due to the formation of CO2. Usually, this system contains a gel-forming agent and alkaline bicarbonates or carbonates which are responsible for the formation of CO2 and thus make the system less dense and float on the gastric fluids. The system contains a gel-forming agent, for example, alginic acid, sodium bicarbonate, and acid neutralizer, which forms a foaming sodium Alg gel called (raft) when it comes in contact with gastric fluids. This raft thus formed floats on the gastric fluids and prevents the reflux of the gastric contents (i.e., gastric acid) into the esophagus, thus acting as a barrier between the stomach and esophagus. A patent assigned to Reckitt and Colman Products Ltd. describes a raft-forming formulation for the treatment of 
Helicobacter pylori infections in the GIT. The composition includes drug, alginic acid, sodium bicarbonate, CaCO3, mannitol, and a sweetener. These ingredients were granulated, and then, citric acid was added to the granules. The formulation thus produced effervescence which resulted in floating.[79,80]Raft-forming drug delivery systems are a revolution in oral drug delivery system. These systems are liquids at room temperature, but when come in contact with body fluids or change in pH undergo gelation, these possess a unique property of temperature dependent and cation-induced gelation. Gelation involves 
the formation of the double helical junction zones followed by aggregation of the double helical segments which form three-dimensional networks by complexation with cations and hydrogen bonding.[81] Various raft-forming system developed for retaining drugs in the stomach for a longer duration of time is summarized in Table 5.
Table 4: Floating drug delivery systems available in the market
Name of product Active ingredient Category Name of company
Zanocin OD Ofloxacin Effervescent floating system Ranbaxy, India
Inon ace tablets Siméthicone Foam‑based floating system Sato Pharma, Japan
Prazopress XL Prazosin Hcl Effervescent and swelling‑based floating 
system
Sun Pharma, Japan
Cafeclor LP Cefaclor Minextab Floating® Galenix, France
Gabapentin GR Gabapentin Polymer‑based swelling technology: 
AcuForm™(In phase three clinical trial)
Depomed, USA
Tramadol LP Tramadol Minextab Floating® Galenix, France
Baclofen GRS Baclofen Coated multi‑layer floating and swelling system Sun PHarma, India
Riomet OD Metformine Hcl Effervescent floating system Ranbaxy, India
Conviron Ferrous sulfate Antacid Ranbaxy, India
Cytotec Misoprostol Bilayer floating capsule PHarmacia Limited, UK
Cifran OD Ciprofloxacin (1 mg) Antibiotic Ranbaxy, India
Almagate flotcoat Al and Mg antacid Antacid ‑
Topalkan Alginic acid, Aluminum and Magnesium salts Antacid Pierre, Fabre drug, Fabrace
Madopar HBS capsule Levodopa (100 mg) and benserazide (25 mg) Antiparkinsonial Roche, USA
Liquid Gaviscon Al Hydroxide (95 mg), Mg carbonate (358 mg) Antacid (in reflux esophagitis) Glaxo Smithline, India
Valrelease Capsule Diazepam (15 mg) Anti anxiety Hoffman‑La Roche, USA
Source: (Srikanth et al., 2011; Jain et al., 2005; Fagregas et al.,1994; Degtiareva et al.,1994; Erni et al.,1987; Washington et al.,1986)[70‑75]
Figure 8: Drug release from swellable systems (Nayak et al., 2010)
Figure 9: Stages of mucoadhesion (Alexander et al., 2011)
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Advances in raft-forming approachThe Algs were used conventionally as an excipient in drug products depending on the thickening, gel-forming, and stabilizing properties. Alg-based raft-forming formulations have been marketed worldwide for over 30 years under various brand names, which includes Gaviscon.[82] They are used for the symptomatic treatment of heartburn and esophagitis and appear to act by a unique mechanism which is quite different from that of traditional antacids. In the presence of gastric acid, Algs precipitate, thus forming a gel. Alg-based raft-forming 
formulations usually contain sodium or potassium bicarbonate which in the presence of gastric acid gets converted into carbon dioxide which becomes entrapped within the gel precipitate, converting it into foam which floats on the surface of the gastric contents, much like a raft on water. The in vitro and in 
vivo studies demonstrated that Alg-based raft system entraps carbon dioxide as well as antacid components contained in the formulations. Thus, they provide a relatively pH-neutral barrier. Several studies have demonstrated that the Alg raft can move preferentially into the esophagus in place, or ahead, 
Drug Floating system (polymer 
and effervescent agent)
Evaluation Reference
Cefuroxime axetil HPMC K4M, HPMC 15 M, HPMC100M, 
NaHCO3
Lag time ‑ 2 min duration more than 12 h and showed in vitro 
release for 12 h and in vivo radiographic studies indicated drug 
in stomach for about 6 h
[97]
Metformin hydrochloride and 
glibenclamide
HPMC K100 and NaHCO3 Lag time ‑ 27 s and duration more than 8 h and showed in vitro 
release for more than 8 h
[98]
Diltiazem hydrochloride HPMC K4M, Na CMC, Carbopol 934 Lag time 1–3 min and duration of 17 h and gave 100% drug 
release in 12 h
[99]
Pioglitazone hydrochloride HPMC5LV, HPMC 15 LV, HPMC50LV, 
ethyl cellulose, NaHCO3
Lag time 60–80 s And duration 18–20 h and gave in vitro drug 
release for more than 24 h
[100]
Propanolol HCl Badam gum, NaHCO3 Lag time<3 min and duration of 6–16 h for different 
formulations and gave in vitro release for more than 12 h
[101]
Cetrizine dihydrochloride and 
bergenin
HPMC, NaHCO3 Lag time<2 min and duration more than 10 h and sustain release 
for more than 12 h was obtained and in vivo studies proved that 
drug was retained in stomach for more than 5 h
[102]
Clarithromycin and 
esomeprazole
Xanthan gum, guar gum, HPMC K4M, 
NaHCO3 agent and porous carrier 
calcium silicate, polypropylene and 
aerosol
It explained the role of porous carriers, cellulosic polymers, and 
natural gums on drug release profiles of esomeprazole core in 
clarithromycin coat gastroretentive tablets in duodenal ulcer 
treatment. and drug release for more than 12 h was obtained 
with minimum lag time
[103]
Furosemide HPMC K4M, HPMC K 15 M, HPMC K 
100M, Chitosan, NaHCO3
Lag time <1 min and duration 8 h and in vitro drug release for 
more than 8 h
[104]
Norfloxacin Guar gum, Na CMC, HPMC 15M, 
NaHCO3
Lag time ‑ 2.75 min−7 min and duration more than 24 h and 
provided sustain release for more than 12 h
[105]
Dextromethorphan 
hydrobromide tablets
HPMC as gel material, sodium 
bicarbonate as gas generating agent, 
hexadecanol as floating assistant agent.
Lag time‑3 min and duration more than 24 h. The data of 
physical parameters were all lie within the limits. Drug release 
at 12 h was more than 85%.
[106]
Baclofen Methocel K 100, Methocel K15 M, 
HPMC E‑6 LV, NaHCO3
Lag time ‑ 3–4 min, duration of floating more than 10 h and 
drug release for more than 10 h and X‑ray imaging in six healthy 
human volunteers revealed a mean gastric retention period of 
5.50±0.7 h
[107]
Glipizide HPMC, EC and MC, NaHCO3 Buoyancy 10‑16 h and in vitro release were found in the range of 
59.25–79.50%. in 8 h
[108]
Lornoxicam HPMC K15, CaCO3 Lag time ‑ <1 min, duration more than 24 h released 55% drug 
after 8 h
[109]
Tizanidine HPMC K4M, HPMC K 15 M, HPMC 
K100M
Buoyancy ‑ 12 h and drug release for more than 12 h and t‑50 
was 5.4 h in radiographic studies and in‑vivo studies in human 
volunteers showed that mean gastric residence time was 
6.2±0.2 h
[110]
Ofloxacin Guar gum, locust bean gum, HPMC 
K100 and NaHCO3
Formulation with locust bean gum and HPMC gave lag time 
2–3 min, duration more than 12 h, and drug 97.8% and 97.33% 
in 12 h
[111]
Aceclofenac HPMC E5 M and Eudragit RS 100, 
NaHCO3
Formulation gave floating time –o8–12 h and showed in vitro 
drug release for more than 8 h
[112]
Nimodipine and its inclusion 
complex with beta cyclodextrin
HPMCK4M, HPMC K 15 M, HPMC15, 
HPMC
K100M, Eudragit RSPO, NaHCO3
Floating duration 24 h and gave release over 24 h with the 
99.89%
[113]
Ciprofloxacin Carbopol 971P, Xanthan gum, HPMC K 
100M, crospovidone, Na, CMC, NaHCO3
Lag time<20 s and duration more than 24 h and gave in vitro 
release for more than 24 h
[114]
Table 5: Different floating systems and their evaluation
(Contd...)
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of acidic gastric contents during the gastroesophageal reflux; some studies further suggest that the raft can act as a physical barrier to reduce the reflux episodes. Although some Alg-based formulations contain antacid components which can provide significant acid neutralization capacity. The efficacy of these formulations so as to reduce heartburn symptoms does not appear to be totally dependent on the neutralization of bulk gastric contents. The strength of the Alg raft is dependent on several factors which include the amount of carbon dioxide generated and entrapped in the raft, the molecular properties of the Alg, and the presence of aluminum or calcium in the antacid components of the formulation. Raft formation occurs rapidly, often within a few seconds of dosing; hence, Alg-containing antacids are thus comparable to traditional antacids for the speed of onset of relief. Since the raft can be retained in the stomach for several hours, thus they provide the additional advantage of longer-lasting relief than that of traditional antacids Alg-based raft-forming formulations have been used to treat reflux symptoms in infants and children and also in the management of heartburn and reflux during the pregnancy.The Gaviscon is effective when used alone, and it is compatible and does not interfere with the activity of antisecretory agents such as cimetidine. Even in case of the introduction of new antisecretory and promotility agents, Alg-rafting formulations will continue to have a role in the treatment of heartburn and reflux symptoms. Their unique non-systemic mechanism of action provides rapid and long-duration relief in case of heartburn and acid reflux symptoms. Besides Gaviscon, other marketed formulations are topalkan which is an effervescent floating liquid Alg preparation and consist of aluminum and magnesium mixture and other is Alg flotcoat which is also FDF and consists of aluminum and magnesium mixture.[83,84]
Advantage of raft-forming systemThese systems are used for the symptomatic treatment of heartburn and esophagitis. They can also be used in laryngopharyngeal reflux (LPR) and GERD; LPR indicates the backflow of stomach contents into the laryngeal and pharyngeal region. It does not interfere with the activity of promotility agent and antisecretory agents such as cimetidine.[85] The raft system 
provides a rapid and long duration of action and may show its action within seconds. It does not interfere with the function of pyloric sphincter. This system helps us to achieve better patient compliance and is also well tolerated.[78,80]
EVALUATION PARAMETERS OF STOMACH 
SPECIFIC FDDSVarious parameters to be evaluated for stomach specific drug delivery system are as follows.
For Single-unit Dosage Forms (e.g., Tablets)During preliminary optimization studies, tablets were evaluated for official tests such as weight variation and friability. Apart from these studies, the formulation will be examined for unofficial tests as detailed as follows.
Floating lag time and floating durationThe buoyancy of the tablets is determined at 37±0.5°C in 100 ml of simulated gastric fluid at pH 1.2 (without pepsin, USP). The duration for which tablet floats is observed visually. The evaluation is conducted in triplicate for each batch of tablets.[86]
In vitro drug releaseThis is determined using USP II apparatus (paddle) stirring at a speed of 50 or 100 rpm at 37±0°C in the simulated gastric fluid of pH1.2 without pepsin. Samples are withdrawn at particular time intervals from the dissolution medium with replacement, and then, they are analyzed for their drug content after appropriate dilution.[87] The in vitro drug release data from drugs are evaluated kinetically using various mathematical models scuh as zero-order, first-order, Higuchi, and Korsmeyer–Peppas model.[88-92]Zero-order model: F = K0 t, where F represents the fraction of drug released in time t, and K0 is the apparent release rate constant or zero-order release constant. The graph is plotted between cumulative percent drug release and time.First-order model: Ln (1–F) = K1st, where F represents the fraction of drug released in time t, and K1 is the first-order release constant. The graph is plotted between log cumulative percent drug release and time.
Drug Floating system (polymer 
and effervescent agent)
Evaluation Reference
Nizatidine HPMC K4M, HPMC K 15 M, Na CMC, 
NaHCO3
Lag time for best formulation HPMC K4M<1 min and floating 
more than 12 h and drug release for 12 h and during in vivo 
in healthy human volunteers was observed and MRT in the 
stomach was found to be 320 min
[115]
Norfloxacin HPMC K4M, HPMC K100M, and 
Xanthan gum, Citric acid
Duration of floating more than 24 h, and tablets were retained 
in stomach for 205±8.4 min in fasting human volunteers 
and in‑vivo studies were also carried out in healthy human 
volunteers and compared with the marketed formulation
[116]
Stavudine HPMC K100M, Na CMC, NaHCO3 Lag time<1 min and in vitro release more than 12 h and floating 
duration more than 10 h
[117]
Atorvastatin calcium Methocel K4M and Methocel K15M, 
NaHCO3 and citric acid
Lag time<1 min and floating time of 20 h of best formulation 
and showed in vitro release for more than 8 h
[118]
Famotidine HPMC K100M, HPMC K 15 M, NaHCO3, 
Citric acid
Lag time<40 s and duration more than 12 h and showed in vitro 
release for more than 8 h
[119]
HPMC: Hydroxypropyl methylcellulose
Table 5: (Continued)
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Mangla, et al.: Gastroretentive systems www.apjhs.comHiguchi model: F = KHt½, where F represents the fraction of drug released in time t, and KH is the Higuchi dissolution constant. The graph is plotted between cumulative percent drug release and square root of time.Korsmeyer–Peppas Model: F = Kptn, where F represents the fraction of drug released in time t, Kp is the rate constant, and n is the release exponent, indicative of the drug release mechanism. The graph exists between log percentage drug release and log time.The Korsmeyer–Peppas model was employed in the in vitro drug release behavior analysis to distinguish between the competing release mechanisms, i.e., Fickian release (diffusion- CR), non-Fickian release (anomalous transport), and case-II transport (relaxation-CR). In case of spheres, a value of n ≤ 0.43 indicates the Fickian release. When the value of n is between 0.43 and 0.85, there is an indication of non-Fickian release (both diffusion 
controlled and swelling controlled drug release). When, n ≥ 0.85, it is case-II transport and this indicates polymer dissolution and polymeric chain enlargement or relaxation.
In vivo evaluation for gastroretentionThis is carried out by means of X-ray or Gamma scintigraphic monitoring which helps to locate the dosage form in the GIT and through which one can predict and correlates the GET and the passage of dosage form in the GIT.[93] Ozdemir et al.[58] (2000) developed bilayer floating tablets of furosemide and for in vivo studies; the part of the drug was replaced by BaSO4 in the release layer. The duration during which tablets stayed in the stomach was examined by radiograms, and it was concluded that tablets stayed in the stomach for about 6 h.
Water uptake studiesWater uptake studies are performed by an equilibrium weight gain method using USP dissolution test apparatus. The tablets are accurately weighed and placed in a dissolution vessel containing 900 ml of 0.1 N HCl (pH 1.2) maintained at 37 ± 0.5°Cat particular speed of rotation. At regular intervals, the tablet was removed from the dissolution vessel, blotted with tissue paper to remove excess water, and reweighed. The percentage water uptake (i.e., the degree of swelling due to absorbed medium) is calculated using the following equation:% water uptake = (Wt/W0)*100Where Wo and Wt are weights of dry and swelled tablet at time 
t, respectively.[86]
For Multiple Unit Dosage Forms (e.g., Floating 
Beads)Besides the in vitro release, duration of floating, and in vivo gastroretention tests, the multiple unit dosage forms are also evaluated for:
Morphological and dimensional analysisThe beads and microspheres shape and size are analyzed with the help of scanning electron microscopy. The size can also be measured using an optical microscope.[87]
Floating propertiesThe time taken by the floating drug formulation to reach to the upper one-third of the dissolution vessel is called buoyancy lag 
time, and the time for which the formulation constantly floats on the surface of the medium called duration of floating is measured simultaneously as a part of dissolution studies.[65]
SUPERPOROUS HYDROGELSThe conventional hydrogels, which are having pore size ranging 
between 10 nm and 10 μm, have very slow process of water absorption and require several hours to reach an equilibrium state during which premature evacuation of the dosage form may occur, while in case of superporous hydrogel, having average pore 
size (>100 μm), swell to equilibrium size within a minute, due to their rapid water uptake by capillary wetting through numerous interconnected open pores.[94] Moreover, they swell gradually to a large size (swelling ratio 100 or more) and are intended to have sufficient mechanical strength to withstand pressure by gastric contractions. This is mostly achieved by a co-formulation with a hydrophilic particulate material, Ac-Di-Sol (croscarmellose sodium). Gupta and Shivakumar[95] developed superporous hydrogels of rosiglitazone using chitosan with glyoxal as a cross-linking agent. They were prepared by gas blowing method. Due to its high swelling properties in acidic pH, it was characterized as superporous hydrogel and used as gastroretentive drug delivery system.
MAGNETIC SYSTEMSMagnetic systems involve the incorporation of the small magnet inside the core or matrix of the system, and another magnet is externally applied on the abdomen region. However, this system provides satisfactory results, but there is a problem of placing the magnet externally at the right position with great accuracy and precision.[36] Urbina et al.[96] developed multiple controlled drug delivery vehicles using magnetic nanoparticle- polymer composites and two types of nanoparticle-polymer composites were prepared and their potential in drug delivery system with multiple controls (magnetically and thermally controlled delivery) was evaluated, and hence, it was proved that magnetic-polymer nanoparticle composites can be used for gastroretentive drug delivery.
BIOADHESIVE OR MUCOADHESIVE DRUG 
DELIVERY SYSTEMSBioadhesive drug delivery systems are aimed to localize a delivery device within the human to enhance the drug absorption in a site-specific manner. In this approach, bioadhesive polymers adhere to the epithelial surface in the stomach and increase GRT of the dosage forms.[7] Mucoadhesion is based on the principle that dosage form can stick to the mucosal surface by different mechanism. The different mechanisms are summarized in Table 6, and various mucoadhesive formulations are detailed in Table 7.
CONCLUSIONBased on the literature surveyed, it may be concluded that gastroretentive drug delivery offers various potential advantages for drug with poor bioavailability due their absorption is restricted to the upper GIT, and they can be delivered efficiently, thereby maximizing their absorption and enhancing absolute bioavailability. Under certain circumstances, the prolongation 
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of gastric residence time of a delivery system is desirable for achieving a better therapeutic benefit of the drug substance. For instance, the drugs that show absorption in the proximal part of the GIT and the drugs which are degraded or less soluble in alkaline pH may be benefitted by prolonging the gastric residence time. Prolonged gastric retention of therapeutic moiety offers many advantages such as improved bioavailability, reduction of drug wastage, and possible reduction of dose size. A controlled drug delivery based on the literature surveyed, it may be concluded that gastroretentive drug delivery offers various potential advantages for drug with poor bioavailability due their absorption is restricted to the upper GIT, and they can be delivered efficiently, thereby maximizing their absorption and enhancing absolute bioavailability. To develop an efficient gastroretentive dosage form is a real challenge to pharmaceutical technology. Indeed, the drug delivery system must remain for a sufficient time in the stomach, which is not compatible with its normal physiology. All these gastroretentive drug delivery systems (high density, floating, expandable or unfoldable or swelling, superporous, bioadhesive, and magnetic systems) are interesting and present their own advantages and disadvantages. In the future, it is expected that they will become of increasing importance, ultimately leading to improved efficiencies of various types of pharmacotherapies.
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